Intravesical Gemcitabine Delivery for Sustained Bladder Exposure
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for bladder cancer, particularly using gemcitabine, face challenges with short dwell times leading to limited therapeutic benefit, high systemic absorption causing toxicity, and local tolerability issues, necessitating improved drug delivery methods to achieve sustained therapeutic concentrations while minimizing side effects.
Innovation Solution
Intravesical administration of gemcitabine using a controlled release system, such as an intravesical drug delivery device or mucoadhesive coating, to maintain therapeutic concentrations in bladder tissues over extended periods, minimizing systemic exposure and reducing toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If high concentrations of gemcitabine are used to achieve therapeutic tissue levels, then therapeutic efficacy is improved, but systemic absorption increases causing gastrointestinal, bladder and bone marrow toxicity
Solution Approach 1:
The patent applies local quality by using intravesical administration to deliver gemcitabine directly to the bladder tissue at high concentrations locally while minimizing systemic exposure. The drug is administered into the bladder lumen where it achieves therapeutic concentrations at the tumor site without requiring high systemic doses, thereby resolving the contradiction between local efficacy and systemic toxicity
Solution Approach 2:
The patent uses the bladder lumen and urine as an intermediary medium to deliver gemcitabine to the tumor tissue. The drug is dissolved in urine or irrigation solution and delivered via catheter, allowing controlled local exposure that mediates between the need for high therapeutic concentrations and the need to avoid systemic absorption and toxicity
2Ease of operation
If short dwell times of 1 to 2 hours are used for intravesical administration, then patient convenience is improved, but therapeutic benefit is limited due to insufficient drug absorption
Solution Approach 1:
The patent applies periodic action by using repeated intravesical administrations of gemcitabine at scheduled intervals. Instead of relying on a single prolonged dwell time, the treatment protocol uses multiple shorter instillations (e.g., weekly or daily schedules) that collectively achieve therapeutic benefit while maintaining patient convenience and allowing bladder emptying between doses
3Reliability
If high doses of gemcitabine are administered intravesically to overcome dwell time limitations, then therapeutic concentration is improved, but local tolerability issues and systemic absorption increase
Solution Approach 1:
The patent applies continuity of useful action by using repeated periodic administrations of gemcitabine intravesically. Rather than using a single high dose that causes local toxicity, the treatment employs continuous or near-continuous low-to-moderate dose administrations over an extended period, maintaining therapeutic concentrations while allowing tissue recovery between doses and improving local tolerability
Data Source
AI summary
Drug delivery devices and methods are provided for administering gemcitabine to a patient in need of treatment of bladder cancer by intravesically administering gemcitabine into the bladder of the patient to achieve a sustained concentration of the gemcitabine in urine in the bladder sufficient to produce a therapeutically effective concentration of the gemcitabine in the tissues of the bladder. In embodiments, the local administration into the patient's bladder is at a mean average amount of from 1 mg/day to about 300 mg/day of the gemcitabine (FBE).